These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 29154920)
1. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance. Scherlinger M; Germain V; Labadie C; Barnetche T; Truchetet ME; Bannwarth B; Mehsen-Cetre N; Richez C; Schaeverbeke T; Joint Bone Spine; 2018 Oct; 85(5):561-567. PubMed ID: 29154920 [TBL] [Abstract][Full Text] [Related]
2. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML; Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center. Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088 [TBL] [Abstract][Full Text] [Related]
4. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087 [TBL] [Abstract][Full Text] [Related]
5. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. Codreanu C; Šírová K; Jarošová K; Batalov A Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591 [TBL] [Abstract][Full Text] [Related]
6. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments. Shimizu T; Kawashiri SY; Sato S; Morimoto S; Minoda S; Kawazoe Y; Kuroda S; Tashiro S; Sumiyoshi R; Hosogaya N; Yamamoto H; Kawakami A Medicine (Baltimore); 2020 Aug; 99(32):e21480. PubMed ID: 32769882 [TBL] [Abstract][Full Text] [Related]
7. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK; Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609 [TBL] [Abstract][Full Text] [Related]
8. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979 [TBL] [Abstract][Full Text] [Related]
9. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments. Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688 [TBL] [Abstract][Full Text] [Related]
10. Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Plevris N; Jones GR; Jenkinson PW; Lyons M; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Din S; Shand AG; Arnott ID; Lees CW Dig Dis Sci; 2019 Jun; 64(6):1660-1667. PubMed ID: 30535885 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908 [TBL] [Abstract][Full Text] [Related]
12. Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K BioDrugs; 2020 Feb; 34(1):89-98. PubMed ID: 31734899 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730 [TBL] [Abstract][Full Text] [Related]
14. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793 [TBL] [Abstract][Full Text] [Related]
16. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. Bakalos G; Zintzaras E Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Clinical Outcomes After Switching from Remicade Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429 [TBL] [Abstract][Full Text] [Related]
19. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583 [TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]